Peptide Cheat Sheet: Every Major Compound, Status & Evidence at a Glance

How to read this cheat sheet

Compounds are listed with regulatory status first, because that single fact changes everything downstream: quality control, legal exposure, and how much the evidence can be trusted. Evidence grades follow our editorial policy: Strong, Moderate, Early clinical, Preclinical-dominant, or Mixed.

The quick-reference table

• BPC-157 — Not FDA-approved; FDA compounding-risk list. Evidence: preclinical-dominant (rodent tendon/gut models). Key risk: no human safety dataset.
• TB-500 — Not FDA-approved; WADA-prohibited. Evidence: preclinical-dominant. Key risk: no human trials of the sold fragment.
• CJC-1295 (DAC) — Not FDA-approved; FDA safety-flagged. Evidence: phase-I pharmacology only. Key risk: multi-day non-pulsatile GH elevation.
• Ipamorelin — Not FDA-approved. Evidence: early clinical; phase-II program failed. Key risk: unknown long-term GH-axis effects.
• GHK-Cu — Cosmetic topical use common; injectable not approved. Evidence: mixed by route. Key risk: route conflation.
• AOD-9604 — Not FDA-approved. Evidence: early clinical; obesity program discontinued. Key risk: efficacy never confirmed.
• MK-677 (ibutamoren) — Not FDA-approved; oral, not a peptide. Evidence: multiple RCTs with mixed outcomes. Key risks: appetite, glucose, edema.
• Semaglutide — FDA-approved for defined indications, prescription-only. Evidence: strong. Key risk: compounded versions are a separate, FDA-warned category.

Each row above compresses a full evidence file. Start with our BPC-157 dosage research review and the TB-500 fragment breakdown, see how CJC-1295 with DAC earned its safety flag, then contrast everything with semaglutide — the one compound here with real trials — and the MK-677 trade-off file.